J Allergy Clin Immunol

AAAAI Conference: Rebamipide may combat low-grade inflammation in post-COVID-19 syndrome patients

March 7, 2024

In this study, researchers examined patients aged 42 to 55 years with post-COVID-19 syndrome using NSAIDs for their joint pain. Their findings, presented at the recent American Academy of Allergy, Asthma, & Immunology Annual Meeting (AAAAI) in Washington, D.C., suggest that rebamipide may be useful for the rehabilitation of patients with post-COVID syndrome.

• 62 patients aged 42-55 years with post-COVID-19 syndrome using NSAIDs for joint pain were divided in two groups: Group 1 (n=34) received rebamipide 100 mg 3 times daily and omeprazole 20 mg daily for 28 days; Group 2 (n=28) received omeprazole alone.
• CRP plasma level before and after intervention was measured by ELISA.
• Group 1 had significant improvement of CRP (pg/mL) in peripheral blood, decreasing from 3.75 [2.82; 4.21] before to 2.05 [1.85; 2.62] (p<0.05) after treatment.
• Group 2 had no significant changes in CRP from before at 3.4 [2.56; 4.0] to after at 3.52 [2.68; 3.9] (p>0.05) treatment with omeprazole alone.
• Rebamipide may be useful in combating low-grade inflammation manifested by elevated CRP and joint symptoms in patients with post-COVID-19 syndrome.

Sources:

Beloglazov, V., et al. (2024, February). J Allergy Clin Immunol. Effect of rebamipide on low-grade inflammation in post COVID-19 syndrome patients. https://www.jacionline.org/article/S0091-6749(23)02102-4/